Boston Scientific Corp (NYSE:BSX) advanced Tuesday after reporting preliminary fourth-quarter sales figures that were in line with the consensus estimate.
The Marlborough, Massachusetts-based medical products company said preliminary sales increased 6.3% on a reported based during the fourth quarter to $2.56 billion. That matched the average estimate of analysts.
READ: Johnson & Johnson third-quarter results beat estimates; raises guidance for 2018
Shares of Boston Scientific rose $0.47, or 1.4%, to $34.89 in New York Stock Exchange trading.
For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion.
Highlights included a 10.9% gain in its urology and pelvic health segment and 6.4% growth in its cardiovascular business.
Contact Dennis Fitzgerald at dennis@proactiveinvestors.com